Canan Alhan

1.7k citations

32 papers · 520 indexed · h-index 13

Co-authors: Arjan A. van de Loosdrecht Theresia M. Westers Gert J. Ossenkoppele Claudia Cali Hetty J. Bontkes Eline M.P. Cremers Corien Eeltink Birgit I. Lissenberg‐Witte
Topics: Acute Myeloid Leukemia Research (30 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers)Hematological disorders and diagnostics (9 papers)
Cited by: Hematology Genetics Emergency Medicine
Journals: Blood European Journal of Cancer British Journal of Haematology
Partner nations: Netherlands Sweden Italy

In The Last Decade

Canan Alhan

23 papers receiving 510 citations

Peers

Countries citing papers authored by Canan Alhan

Since Specialization

Citations

This map shows the geographic impact of Canan Alhan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Canan Alhan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Canan Alhan more than expected).

Fields of papers citing papers by Canan Alhan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Canan Alhan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Canan Alhan. The network helps show where Canan Alhan may publish in the future.

Co-authorship network of co-authors of Canan Alhan

This figure shows the co-authorship network connecting the top 25 collaborators of Canan Alhan. A scholar is included among the top collaborators of Canan Alhan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Canan Alhan. Canan Alhan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of Machine‐Assisted, Human‐Centred Bone Marrow Cell Classification: Feasibility Analysis in Patients With Myelodysplastic Syndromes 2025 ·eJHaem ·Kíyoyuki Ogata,(unknown),Leonie Saft,(unknown),(unknown),Canan Alhan,Carole Almire,(unknown),(unknown),Naoko Chiba,(unknown),(unknown),(unknown),(unknown),(unknown),Nicolas Chapuis,Orianne Wagner‐Ballon,Arjan van de Loosdrecht,Yumi Yamamoto	0
2	Validation of the diagnostic potential of 17 immunophenotypic core markers defined by the ELN‐iMDS‐Flow Working Group in an independent cohort of patients with MDS 2025 ·HemaSphere ·(unknown),Canan Alhan,Theresia M. Westers,Arjan A. van de Loosdrecht	1
3	Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome 2021 ·Annals of Hematology ·Dolores Subirá,Canan Alhan,Uta Oelschlaegel,Anna Porwit,Katherina Psarra,Theresia M. Westers,(unknown),Lars Nilsson,Arjan A. van de Loosdrecht,Dunia de Miguel	3
4	Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)‐mutant myelodysplastic syndromes subtype 2021 ·British Journal of Haematology ·Carolien Duetz,Theresia M. Westers,(unknown),Eline M.P. Cremers,Canan Alhan,(unknown),Heleen Visser-Wisselaar,Dana Chiţu,Aniek O. de Graaf,Linda Smit,Joop H. Jansen,Arjan A. van de Loosdrecht	7
5	Dysplasia andPNH‐type cells in bone marrow aspirates of myelodysplastic syndromes 2021 ·Cytometry Part B Clinical Cytometry ·Theresia M. Westers,Canan Alhan,Heleen Visser-Wisselaar,Dana Chiţu,Arjan A. van de Loosdrecht	1
6	Machine Learning-Based Flow Cytometry Diagnostics in Myelodysplastic Syndromes: Validation in the HOVON89 Clinical Trial (EudraCT 2008-002195-10) 2020 ·Blood ·Carolien Duetz,Sofie Van Gassen,Theresia M. Westers,(unknown),Eline M.P. Cremers,Canan Alhan,Costa Bachas,(unknown),Heleen Visser-Wisselaar,Dana Chiţu,Aniek O. de Graaf,Joop H. Jansen,Yvan Saeys,Arjan van de Loosdrecht	1
7	Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes 2016 ·Haematologica ·Eline M.P. Cremers,Theresia M. Westers,Canan Alhan,Claudia Cali,Heleen Visser-Wisselaar,Dana Chiţu,Vincent H. J. van der Velden,Jeroen G. te Marvelde,Saskia K. Klein,Petra Muus,Edo Vellenga,(unknown),(unknown),Pierre W. Wijermans,Marian Stevens‐Kroef,(unknown),Joop H. Jansen,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht	44
8	Good's syndrome: an uncommon cause of therapy-resistant diarrhoea. 2016 ·PubMed ·Maria Disselhorst,Chris Dickhoff,Canan Alhan	5
9	Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias 2015 ·European Journal of Cancer ·Eline M.P. Cremers,Theresia M. Westers,Canan Alhan,Claudia Cali,Mariëlle J. Wondergem,Pino J. Poddighe,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht	24
10	The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system 2015 ·Leukemia ·Canan Alhan,Theresia M. Westers,Eline M.P. Cremers,Claudia Cali,Birgit I. Lissenberg‐Witte,G.J. Ossenkoppele,Arjan A. van de Loosdrecht	27
11	Immunophenotyping for diagnosis and prognosis in MDS: Ready for general application? 2014 ·Best Practice & Research Clinical Haematology ·Eline M.P. Cremers,Canan Alhan,Theresia M. Westers,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht	10
12	Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes 2014 ·Cytometry Part B Clinical Cytometry ·Canan Alhan,Theresia M. Westers,(unknown),(unknown),Gerwin Huls,Birgit I. Lissenberg‐Witte,Francesca Buchi,Valeria Santini,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht	12
13	Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts 2013 ·Leukemia Research ·(unknown),Nic J.G.M. Veeger,Marinus van Marwijk Kooy,Aart Beeker,Okke de Weerdt,Martijn de Groot,Canan Alhan,Mels Hoogendoorn,L. Laterveer,Arjan A. van de Loosdrecht,Jan Koedam,Edo Vellenga,Gerwin Huls	24
14	Azacitidine differentially affects CD4pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes 2012 ·Leukemia Research ·Hetty J. Bontkes,Jurjen M. Ruben,Canan Alhan,Theresia M. Westers,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht	34
15	Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study 2012 ·Haematologica ·Matteo Giovanni Della Porta,Cristina Picone,Cristiana Pascutto,Luca Malcovati,Hideto Tamura,Hiroshi Handa,Magdalena Czader,Sylvie Freeman,Paresh Vyas,Anna Porwit,Leonie Saft,Theresia M. Westers,Canan Alhan,Claudia Cali,Arjan A. van de Loosdrecht,(unknown)	110
16	MULTICENTRE VALIDATION OF A REPRODUCIBLE FLOW CYTOMETRIC SCORE FOR THE DIAGNOSIS OF LOWRISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A EUROPEAN LeukemiaNET STUDY 2011 ·Cytometry Part A ·Cristina Picone,(unknown),Laura Vanelli,Luca Malcovati,Cristiana Pascutto,Kíyoyuki Ogata,Hideto Tamura,(unknown),Magdalena Czader,Sylvie Freeman,Paresh Vyas,Anna Porwit,(unknown),Theresia M. Westers,Canan Alhan,Claudia Cali,Arjan A. van de Loosdrecht,Mario Cazzola,Matteo Giovanni Della Porta	1
17	287 Validation of a flow cytometric scoring system for the prognostication of the myelodysplastic syndromes; A retrospective cohort study 2011 ·Leukemia Research ·Canan Alhan,(unknown),Claudia Cali,G. J. Ossenkoppele,Arjan A. van de Loosdrecht	0
18	Role of immune responses in the pathogenesis of low‐risk MDS and high‐risk MDS: implications for immunotherapy 2011 ·British Journal of Haematology ·(unknown),Arjan A. van de Loosdrecht,Canan Alhan,Gert J. Ossenkoppele,Theresia M. Westers,Hetty J. Bontkes	79
19	Expression of C-Type Lectin-Like Molecule-1 (CLL-1) on Stem Cells Might Discriminate De Novo Acute Myeloid Leukemia from Acute Myeloid Leukemia Originating from Myelodysplastic Syndromes 2008 ·Blood ·Theresia M. Westers,Monique Terwijn,Canan Alhan,(unknown),Claudia Cali,Angèle Kelder,Anna van Rhenen,Gerrit Jan Schuurhuis,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht	0
20	Do peripheral blasts count in myelodysplastic syndromes? 2008 ·Leukemia Research ·Canan Alhan,Theresia M. Westers,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht	2

About Canan Alhan

Canan Alhan is a scholar working on Hematology, Genetics and Emergency Medicine, having authored 32 papers that have together received 520 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (30 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers) and Hematological disorders and diagnostics (9 papers). The work is most often cited by research in Hematology (480 citations), Genetics (203 citations) and Emergency Medicine (107 citations). Canan Alhan has collaborated with scholars based in Netherlands, Sweden and Italy. Frequent co-authors include Arjan A. van de Loosdrecht, Theresia M. Westers, Gert J. Ossenkoppele, Claudia Cali, Hetty J. Bontkes, Eline M.P. Cremers, Corien Eeltink, Birgit I. Lissenberg‐Witte, Maurice J. D. L. van der Vorst and Martine E.D. Chamuleau. Their work appears in journals such as Blood, European Journal of Cancer and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact